| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/18/2002 | EP1240193A2 Peptide fragments of colostrinin |
| 09/18/2002 | EP1240172A1 New aminopropylphosphinic acids |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240164A1 Benzazole derivatives and their use as jnk modulators |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240146A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1240144A2 Compound having effect of promoting neuron differentiation |
| 09/18/2002 | EP1240143A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240142A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240141A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1239883A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239882A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239880A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239879A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239878A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239865A1 Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract |
| 09/18/2002 | EP1239861A2 Combination of cyamemazine and an atypical neuroleptic |
| 09/18/2002 | EP1239860A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/18/2002 | EP1239855A2 Method for the prevention and/or treatment of atherosclerosis |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239847A1 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239844A1 Process for producing nanometer particles by fluid bed spray-drying |
| 09/18/2002 | EP1239839A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 09/18/2002 | EP1239832A2 Suspension comprising oxcarbazepine |
| 09/18/2002 | EP1000034B1 Substituted 6-alkylphenanthridines |
| 09/18/2002 | EP0950056B1 N-(pyridinylamino)isoindolines and related compounds |
| 09/18/2002 | EP0934259B1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 09/18/2002 | EP0932414B1 USES OF COMPOSITIONS WITH alpha-LACTALBUMEN BASE |
| 09/18/2002 | EP0929516B1 Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect |
| 09/18/2002 | EP0904260B1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids |
| 09/18/2002 | EP0858461B1 Fused tropane-derivatives as neurotransmitter reuptake inhibitors |
| 09/18/2002 | EP0841923B1 1h-4(5)-substituted imidazole derivatives |
| 09/18/2002 | EP0828486B1 Use of pyrrolidine derivatives for treating alcoholism |
| 09/18/2002 | EP0823889B1 1,3-propane diol derivatives as bioactive compounds |
| 09/18/2002 | EP0790237B1 Bicyclolactam compounds, use of the same and intermediate in the production of the same |
| 09/18/2002 | EP0772600B1 1,2-substituted imidazolyl compounds for the treatment of inflammation |
| 09/18/2002 | EP0767793B1 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines |
| 09/18/2002 | EP0764158B1 Benzopyrans and their use as therapeutic agents |
| 09/18/2002 | EP0757681B1 CONDENSED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS GnRH ANTAGONISTS |
| 09/18/2002 | CN1370238A Human poly(ADP-ribose) polymerase 2 materials and methods |
| 09/18/2002 | CN1370176A Subsstituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370174A 2,3-benzodiazepine derivatives |
| 09/18/2002 | CN1370173A Isomeric fused pyrrolocarbazoles and isoindolones |
| 09/18/2002 | CN1370169A Substituted heterocycle fused gamma-carbolines |
| 09/18/2002 | CN1370168A Novel spiro compounds |
| 09/18/2002 | CN1370159A Indole derivatives and their use for treatment of osteoporosis amongst other applications |
| 09/18/2002 | CN1370154A Aminothiazole derivatives and their use as CRF receptor ligands |
| 09/18/2002 | CN1370143A Propanoic acid derivatives that inhibit binding of integrins to their receptors |
| 09/18/2002 | CN1370078A Prion protein peptides and uses thereof |
| 09/18/2002 | CN1370073A Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 09/18/2002 | CN1370044A Nitric oxide donors for inducing neurogenesis |
| 09/18/2002 | CN1369298A Capsule for treating hemiplegia and rheumatism |
| 09/18/2002 | CN1369275A Sobering-up agent |
| 09/18/2002 | CN1369265A Application of saccinic acid in preparing antianxiety medicine |
| 09/18/2002 | CN1091108C Diphenylmethylene piperidine derivatives, its prepn. medicinal compsns. contg. them and application thereof |
| 09/18/2002 | CN1090969C Fatigue relieving medicine for driver |
| 09/18/2002 | CN1090968C Medicinal analgesic and sedative and preparing process thereof |
| 09/18/2002 | CN1090955C Chinese medicine for dropping drag and its preparing process |
| 09/18/2002 | CN1090944C Pharmacetical for preventing and treating senile dementia and depression, its prepn. process |
| 09/18/2002 | CN1090920C Kelp product and its prodn. method and application |
| 09/18/2002 | CA2403605A1 Heterocycle derivatives and drugs |
| 09/17/2002 | US6452054 Psychological disorders |
| 09/17/2002 | US6452015 Cyclobutaindolecarboxamide compounds |
| 09/17/2002 | US6452001 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 09/17/2002 | US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis |
| 09/17/2002 | US6451860 Methods for treating depression and other disorders using optically pure (−)-bupropion |
| 09/17/2002 | US6451858 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 09/17/2002 | US6451854 α-amino acid phenyl ester derivatives |
| 09/17/2002 | US6451849 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| 09/17/2002 | US6451848 Compositions and methods comprising morphine gluconate |
| 09/17/2002 | US6451842 Cyclic amine derivatives and their use as drugs |
| 09/17/2002 | US6451838 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/17/2002 | US6451819 Pyrrolidine-3-yl-sulfanyl, or sufonyl or sufinyl derivatives used in the treatment of neurodegenerative diseases |
| 09/17/2002 | US6451818 Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline |
| 09/17/2002 | US6451810 Amide substituted imidazoquinolines |
| 09/17/2002 | US6451804 Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
| 09/17/2002 | US6451803 N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders |
| 09/17/2002 | US6451795 Central neurodegenerative diseases |
| 09/17/2002 | US6451794 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors |
| 09/17/2002 | US6451791 Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| 09/17/2002 | US6451789 Central nervous system disorders; cognition activators |
| 09/17/2002 | US6451786 Tyrosine kinase inhibitors |
| 09/17/2002 | US6451783 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 09/17/2002 | US6451776 Water soluble prodrugs of hindered alcohols |
| 09/17/2002 | US6451761 N′N′-dichlorinated omega-amino acids and uses thereof |
| 09/17/2002 | US6451577 Human uridine disphosphate galactose-4-epimerase |
| 09/17/2002 | US6451541 Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc |
| 09/17/2002 | US6451343 A-(methoximino)-a-(1-azabicyclo(2.2.2)oct-3-yl)acetonitrile hydrochloride amyloid precursor protein intensifier |
| 09/17/2002 | US6451307 3′-exonuclease, production and use thereof |
| 09/17/2002 | CA2243459C Human antibodies that bind human tnf.alpha. |
| 09/17/2002 | CA2113118C Novel growth factor-responsive progenitor cells which can be proliferated in vitro |
| 09/17/2002 | CA2045473C Compositions for treating ischemia-related neuronal damage |
| 09/17/2002 | CA2042974C Use of a 1-(2-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the manufacture of a medicament for the treatment of cerebral and neuronal diseases |